BRIEF-Interim Analysis From Phase 3 Trial Suggests Efficacy Of 2 Doses Of CoronaVac Is 83.5% Against Symptomatic COVID-19- The Lancet

July 8 (Reuters) -

* INTERIM ANALYSIS FROM PHASE 3 TRIAL SUGGESTS EFFICACY OF 2 DOSES OF CORONAVAC IS 83.5% AGAINST SYMPTOMATIC COVID19- THE LANCET

* CORONAVAC HAS HIGH EFFICACY AGAINST PCR-CONFIRMED SYMPTOMATIC COVID-19 WITH A GOOD SAFETY AND TOLERABILITY PROFILE - THE LANCET